Date: 2015-05-05
Type of information: Private placement
Company: Inovio Pharmaceuticals (USA - PA)
Investors:
Amount: $82.1 million
Funding type: private placement
Planned used: Inovio Pharmaceuticals intends to use the net proceeds received from the sale of the common stock for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies and technologies that complement its business.
Others: * On May 5, 2015, Inovio Pharmaceuticals closed its previously announced underwritten public offering of 10,925,000 shares of the Company’s common stock, including 1,425,000 shares of common stock issued pursuant to the underwriter’s exercise of its option, at the public offering price of $8.00 per share. The gross proceeds of this offering were $87.4 million. Net proceeds to the Company, after deducting the underwriter’s discounts and commission and other estimated offering expenses payable by the Company, were approximately $82.1 million. Piper Jaffray & Co. and Stifel acted as joint bookrunning managers for the offering. H.C. Wainwright & Co., LLC, Brean Capital, LLC and Maxim Group LLC acted as co-managers of the offering.
Therapeutic area: Cancer - Oncology - Infectious diseases
